Feasibility Study: Nanotechnology Herbal Pharma Startup

Conducted a comprehensive feasibility study for an Israeli startup developing nanotechnology-based delivery systems for herbal pharmaceutical products. The company was seeking angel investment and needed a rigorous, investor-ready assessment of their technology, market opportunity, and commercial viability.

Technology Assessment — Evaluated the nanotechnology platform for delivering herbal active compounds, including bioavailability improvements, formulation stability, and scalability of the manufacturing process. Assessed the technical differentiation against existing herbal pharma delivery methods.

Market Analysis — Mapped the global herbal pharmaceutical market, identifying target segments where nanotechnology-enhanced delivery offered a defensible advantage. Analyzed regulatory pathways across key markets including the US, EU, and Israel.

Commercial Viability — Built financial projections, estimated capital requirements for scale-up, and modeled unit economics across different go-to-market scenarios. Identified key risks and mitigation strategies for early-stage investors.

Investment Readiness — Structured the findings into an investor-facing feasibility report designed to support angel round fundraising, including competitive positioning, IP landscape analysis, and milestone-based funding recommendations.

The intersection of nanotechnology and herbal medicine sits at the frontier of pharmaceutical innovation. The startup needed someone who understood both the science of plant-based therapeutics (from 23 years in the Indian Forest Service and published research on medicinal plants) and the commercial rigor required to convince sophisticated investors.

Delivered a comprehensive feasibility report that gave the founding team and prospective investors a clear-eyed view of the opportunity, the risks, and the capital pathway forward.